Modafinil-Induced Irritability and Aggression?

Ranjan, Sanjeev; Chandra, Prabha S.

doi:10.1097/01.jcp.0000185346.77966.a4

Cited by 20 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is important both for theoretical and practical reasons. Our finding of elevated arousal and NA with modafinil is consistent with a previous report of increased subjective anxiety and aggression following modafinil administration, 6,17 although it is in contrast to claims that modafinil does not elevate negative mood states. 4 Earlier research by our group found that modafinil heightens apparent sympathetic outflow increasing heart rate, systolic blood pressure, catecholamines but decreases muscle sympathetic nerve activity 18 and does not cause analgesia.…”

Section: Discussionsupporting

confidence: 91%

A Randomized, Double-Blind, Crossover Trial of Modafinil on Mood

Taneja¹,

Haman²,

Shelton³

et al. 2007

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

Modafinil, a medication for the excessive sleepiness associated with narcolepsy, has been hypothesized to improve not just alertness but mood as well. The purpose of this study was to determine how treatment with modafinil affects mood in healthy volunteers. Normal healthy volunteers (n = 12, 10 men and 2 women; 30-44 years) underwent a 3-day, counterbalanced, randomized, crossover, inpatient trial of modafinil (400 mg daily) versus placebo with 4-day washout period between 2 treatments. Mood was assessed daily using both the Positive and Negative Affect Schedule and a general mood scale, which consisted of 10 bipolar adjective ratings based on a severity scale ranging from 1 to 10. Modafinil increased general mood and Negative Affect scales relative to placebo and had a significant effect on Positive Affect scales. These results suggest that modafinil may have general mood-elevating effects accompanied by increased negative affect (anxiety). The findings may have implications for clinical practice, in particular for the adjunctive use of modafinil in treatment-resistant depression.

show abstract

Section: Discussionsupporting

confidence: 91%

A Randomized, Double-Blind, Crossover Trial of Modafinil on Mood

Taneja¹,

Haman²,

Shelton³

et al. 2007

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…One case report described a manic switch in a patient with treatment-resistant bipolar depression treated with modafinil, 213 and 2 cases of modafinil-induced irritability and aggression in 2 bipolar patients have been described. 214 A proprietary formulation of the nucleoside uridine, Uridine RG2417 (Repligen Corp.), a biological compound essential for the synthesis of DNA and RNA, is currently in development for the treatment of neuropsychiatric disorders and neurodegenerative diseases. A previous study suggested that RG2133, the prodrug of RG2419, had antidepressant-like effects in an animal model of depression.…”

Section: Other Drugs Being Tested In Bpdmentioning

confidence: 99%

Bipolar disorder: candidate drug targets

Zarate

Manji

2008

Mount Sinai J Medicine

View full text Add to dashboard Cite

Current pharmacotherapy for bipolar disorder is generally unsatisfactory for a large number of patients. Even with adequate modern bipolar pharmacological therapies, many afflicted individuals continue to have persistent mood episode relapses, residual symptoms, functional impairment, and psychosocial disability. Creating novel therapeutics for bipolar disorder is urgently needed. Promising drug targets and compounds for bipolar disorder worthy of further study include both systems and intracellular pathways and targets. Specifically, the purinergic system, the dynorphin opioid neuropeptide system, the cholinergic system (muscarinic and nicotinic systems), the melatonin and serotonin [5-hydroxytryptamine receptor 2C] system, the glutamatergic system, and the hypothalamic-pituitary adrenal axis have all been implicated. Intracellular pathways and targets worthy of further study include glycogen synthase kinase-3 protein, protein kinase C, and the arachidonic acid cascade.

show abstract

“…Although both controlled studies did not show an increased risk of switching in the intervention group, several case reports described modafinil-induced mania or hypomania [51,52], suggesting that caution is necessary during its use in BD.…”

Section: Modafinilmentioning

confidence: 96%

New Drugs for Bipolar Disorder

Sanches¹,

Soares²

2011

Curr Psychiatry Rep

View full text Add to dashboard Cite

Bipolar disorder (BD) is one of the most potentially severe mental disorders. Literature data indicate that despite the current available treatments, a large proportion of patients do not achieve complete remission, with consequent residual symptoms and chronic impairment. We carried out a comprehensive review of new pharmacologic treatments for BD. Even though the core treatment of BD likely will not likely undergo substantial changes over the next few years, many promising results with respect to new augmentation strategies were identified. New treatments for bipolar depression and for BD-related cognitive impairment seem to represent particularly fertile areas of research.

show abstract

Modafinil-Induced Irritability and Aggression?

Cited by 20 publications

References 7 publications

A Randomized, Double-Blind, Crossover Trial of Modafinil on Mood

A Randomized, Double-Blind, Crossover Trial of Modafinil on Mood

Bipolar disorder: candidate drug targets

New Drugs for Bipolar Disorder

Contact Info

Product

Resources

About